Legend Biotech Corp. (LEGN)
17.79
-0.83
(-4.46%)
USD |
NASDAQ |
Oct 12, 16:00
17.80
+0.01
(+0.06%)
After-Hours: 20:00
Legend Biotech Cash from Investing (Quarterly) : -120.10M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -120.10M |
| March 31, 2026 | -168.50M |
| December 31, 2025 | 640.22M |
| September 30, 2025 | -20.08M |
| June 30, 2025 | -165.30M |
| March 31, 2025 | 256.64M |
| December 31, 2024 | -87.84M |
| September 30, 2024 | 328.46M |
| June 30, 2024 | -696.81M |
| March 31, 2024 | -396.81M |
| December 31, 2023 | 405.10M |
| September 30, 2023 | -211.44M |
| June 30, 2023 | -127.62M |
| March 31, 2023 | 17.93M |
| Date | Value |
|---|---|
| December 31, 2022 | 23.99M |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | -232.50M |
| December 31, 2021 | 96.51M |
| September 30, 2021 | -105.67M |
| June 30, 2021 | -168.67M |
| March 31, 2021 | -17.12M |
| December 31, 2020 | 61.08M |
| September 30, 2020 | -58.62M |
| June 30, 2020 | -9.212M |
| March 31, 2020 | -17.50M |
| December 31, 2019 | 113.45M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Gilead Sciences, Inc. | -10.35B |
| Ionis Pharmaceuticals, Inc. | 23.50M |
| Johnson & Johnson | -1.11B |
| Arbutus Biopharma Corp. | -1.664M |
| Capricor Therapeutics, Inc. | -48.76M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -20.87M |
| Cash from Financing (Quarterly) | 168.05M |
| Free Cash Flow | -264.16M |
| Free Cash Flow Per Share (Quarterly) | -0.2141 |
| Free Cash Flow to Equity (Quarterly) | 69.62M |
| Free Cash Flow to Firm (Quarterly) | -38.01M |
| Free Cash Flow Yield | -7.94% |